Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

IF 12.8 1区医学 Q1 DERMATOLOGY

Journal of the American Academy of Dermatology Pub Date : 2025-07-12 DOI:10.1016/j.jaad.2025.07.013

Andrew Blauvelt, Petr Arenberger, Maxwell B. Sauder, Megan Couvillion, Roman G. Rubio, Nicholas E. Vlahakis, Sibel Ucpinar, Grace Ma, Elena Hitraya, Mera K. Tilley, Kim A. Papp, STRIDE investigators

引用次数: 0

Abstract

ESK-001, a novel allosteric, highly selective oral TYK2 inhibitor in development for treatment of immune-mediated disorders, was well-tolerated, and achieved high levels of target inhibition in Phase 1 studies with healthy volunteers.

查看原文本刊更多论文

口服ESK-001对中重度斑块型银屑病患者TYK2的高选择性、变抑性抑制：STRIDE的结果，这是一项为期12周、随机、双盲、安慰剂对照、剂量范围的2期研究

ESK-001是一种新型的变构性、高选择性口服TYK2抑制剂，正在开发中，用于治疗免疫介导性疾病，在健康志愿者的1期研究中具有良好的耐受性，并实现了高水平的靶标抑制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Academy of Dermatology 医学-皮肤病学

CiteScore

8.60

自引率

5.80%

发文量

2023

审稿时长

49 days

期刊介绍： The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.